October 2025 in “F1000Research” In this case series, the authors reported that postmenopausal hyperandrogenism should be carefully evaluated to diagnose potential androgen-secreting tumors, with Sertoli-Leydig cell tumors identified as a common cause.
36 citations
,
May 2011 in “The Journal of Clinical Endocrinology & Metabolism” Treatment with a hormone agonist can reduce excess male hormones in postmenopausal women without surgery.
July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” In this study of a postmenopausal woman with hyperandrogenism, GnRH agonist treatment significantly reduced testosterone levels, suggesting the androgen excess was ovarian in origin and indicating the potential of using GnRH agonists as a conservative treatment option when surgery is not feasible.
July 2024 in “Journal of the ASEAN Federation of Endocrine Societies” In this case study, a 69-year-old woman with signs of virilization and high testosterone levels was found to have an ovarian steroid cell tumor, highlighting the importance of systematically investigating such symptoms in postmenopausal women to determine the underlying etiology and prevent poor prognosis.
1 citations
,
July 2022 in “BMC Women s Health” This report describes a rare case of elevated serum DHEAS levels in a postmenopausal woman, linked to an ovarian sex cord-stromal tumor rather than the adrenal glands, challenging common assumptions about androgen sources.